Alcon delivered a strong fourth quarter with sales reaching $2.7 billion, a 9% increase over the prior year. While reported operating margins and EPS faced pressure from increased R&D and marketing investments for new launches, core results remained resilient with core diluted EPS growing 8%. The company successfully navigated softer markets through price increases and a wave of innovative product introductions in both Surgical and Vision Care segments.

Alcon delivered a strong Q3 2025 performance with revenue reaching $2.6 billion and net income of $237 million. Growth was led by Vision Care and Surgical segments, particularly in equipment and ocular health. EPS came in at $0.48, with core EPS at $0.79.

Alcon delivered solid second-quarter 2025 results with sales reaching $2.6 billion, a 4% increase on a reported basis. Diluted EPS was $0.35, and core diluted EPS stood at $0.76. The company generated strong free cash flow in the first half of the year and returned $287 million to shareholders. Strategic moves included the launch of Tryptyr for dry eye disease and the announced acquisition of STAAR Surgical to expand its myopia correction portfolio.

Alcon posted stable revenues of $2.5B in Q1 2025, with net income rising to $350M. Adjusted EPS was $0.73, reflecting continued innovation-led performance despite market softness in the US.

Alcon achieved net sales of $2.5 billion in Q4 2024, a 6% increase over the previous year. Operating income rose significantly to $395 million, with an operating margin expansion of 7 percentage points. The company reported diluted EPS of $0.57 and core diluted EPS of $0.72.